Purpose of review: We aimed to reach an Italian multidisciplinary consensus on some crucial aspects of treatment decision making in CRSwNP, following 2 years of clinical experience in order to support specialists in the management of CRSwNP in clinical practice. We addressed issues relating to therapeutic decision-making and shared criteria for the treatment choice, as well as appropriate timing and criteria for evaluating treatment response, and highlighted the need for repeated multidisciplinary assessments. Recent findings: A national survey has been conducted recently to understand how rhinology practice has changed in Italy with the advent of biologics and how this affects patients with uncontrolled, severe CRSwNP. Despite the many published consensus documents, practical recommendations, and protocols on the use of biologics in CRSwNP, heterogenous behaviors in practice are still observed mainly conditioned by the novelty of the topic. The consensus procedure followed a modified Delphi approach. The scientific board included 18 otorhinolaryngologists and 8 allergists, who selected the 4 main topics to be addressed and developed overall 20 statements. Consensus on these statements was sought by a larger group of 48 additional experts, through two rounds of voting, the first web-based, the second in presence with discussion and possible refinement of the statements. The statements reaching an average score ≥ 7 at the second voting round were approved. Five statements were proposed for each of the following topics: baseline evaluation of patients eligible for biologic therapy; choice between different therapeutic options; assessment of the response to biologic treatment; multidisciplinary management. At the first voting round, 19 out of the 20 statements reached a mean score ≥ 7. Following the discussion and a few consequent amendments, at the second round of voting all the 20 statements were approved.

Multidisciplinary decision-making—italian consensus after two years of real practice on the management of severe uncontrolled CRSwNP by biologics (ITACA Study) / De Corso, Eugenio; Pipolo, Carlotta; Caminati, Marco; Cantone, Elena; Seccia, Veronica; Cecchi, Lorenzo; Nettis, Eustachio; Garzaro, Massimiliano; Ottaviano, Giancarlo; Gelardi, Matteo; Cavaliere, Carlo; Heffler, Enrico; Pagella, Fabio; Pasquini, Ernesto; Trimarchi, Matteo; Gallo, Stefania; La Mantia, Ignazio; Torretta, Sara; Mattavelli, Davide; Caruso, Cristiano; Matucci, Andrea; Vultaggio, Alessandra; Bellocchi, Gianluca; Ciufelli, Matteo Alicandri; Fm, Passali; Senna, Gianenrico. - In: CURRENT ALLERGY AND ASTHMA REPORTS. - ISSN 1529-7322. - (2024). [10.1007/s11882-024-01135-z]

Multidisciplinary decision-making—italian consensus after two years of real practice on the management of severe uncontrolled CRSwNP by biologics (ITACA Study)

Cavaliere, Carlo;
2024

Abstract

Purpose of review: We aimed to reach an Italian multidisciplinary consensus on some crucial aspects of treatment decision making in CRSwNP, following 2 years of clinical experience in order to support specialists in the management of CRSwNP in clinical practice. We addressed issues relating to therapeutic decision-making and shared criteria for the treatment choice, as well as appropriate timing and criteria for evaluating treatment response, and highlighted the need for repeated multidisciplinary assessments. Recent findings: A national survey has been conducted recently to understand how rhinology practice has changed in Italy with the advent of biologics and how this affects patients with uncontrolled, severe CRSwNP. Despite the many published consensus documents, practical recommendations, and protocols on the use of biologics in CRSwNP, heterogenous behaviors in practice are still observed mainly conditioned by the novelty of the topic. The consensus procedure followed a modified Delphi approach. The scientific board included 18 otorhinolaryngologists and 8 allergists, who selected the 4 main topics to be addressed and developed overall 20 statements. Consensus on these statements was sought by a larger group of 48 additional experts, through two rounds of voting, the first web-based, the second in presence with discussion and possible refinement of the statements. The statements reaching an average score ≥ 7 at the second voting round were approved. Five statements were proposed for each of the following topics: baseline evaluation of patients eligible for biologic therapy; choice between different therapeutic options; assessment of the response to biologic treatment; multidisciplinary management. At the first voting round, 19 out of the 20 statements reached a mean score ≥ 7. Following the discussion and a few consequent amendments, at the second round of voting all the 20 statements were approved.
2024
biological therapy; chronic rhinosinusitis with nasal polyps; dupilumab; mepolizumab; multidisciplinary management; omalizumab; response assessment; type 2 inflammation
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Multidisciplinary decision-making—italian consensus after two years of real practice on the management of severe uncontrolled CRSwNP by biologics (ITACA Study) / De Corso, Eugenio; Pipolo, Carlotta; Caminati, Marco; Cantone, Elena; Seccia, Veronica; Cecchi, Lorenzo; Nettis, Eustachio; Garzaro, Massimiliano; Ottaviano, Giancarlo; Gelardi, Matteo; Cavaliere, Carlo; Heffler, Enrico; Pagella, Fabio; Pasquini, Ernesto; Trimarchi, Matteo; Gallo, Stefania; La Mantia, Ignazio; Torretta, Sara; Mattavelli, Davide; Caruso, Cristiano; Matucci, Andrea; Vultaggio, Alessandra; Bellocchi, Gianluca; Ciufelli, Matteo Alicandri; Fm, Passali; Senna, Gianenrico. - In: CURRENT ALLERGY AND ASTHMA REPORTS. - ISSN 1529-7322. - (2024). [10.1007/s11882-024-01135-z]
File allegati a questo prodotto
File Dimensione Formato  
De Corso_Multidisciplinary decision_2024.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.69 MB
Formato Adobe PDF
1.69 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1706350
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact